A Randomised Dose-Response Study of Prophylactic Methoxamine Infusion for Preventing Spinal-induced Hypotension during Cesarean Delivery

Feng Fu, Yu-Wen Tang, Hong Chen, Cuicui Jiao, Na Ma, Xinzhong Chen

This study, conducted by researchers at Zhejiang University, establishes the optimal dosing for methoxamine—a selective $\alpha_1$-adrenergic agonist—to prevent low blood pressure during Cesarean sections under spinal anesthesia. By testing four different infusion rates, the team determined the doses required to prevent hypotension in 50% (ED50) and 95% (ED95) of patients, providing a new clinical benchmark for obstetric anesthesia.

TL;DR

Researchers have identified the effective doses of methoxamine infusion (ED50: 2.178 $\mu$g/kg/min; ED95: 4.821 $\mu$g/kg/min) needed to prevent spinal-induced hypotension during Cesarean deliveries. This study suggests that methoxamine is a viable, potentially heart-protective alternative to the current gold standard, phenylephrine.

What Problem Does This Paper Address?

Spinal anesthesia is the preferred method for Cesarean sections, but it comes with a major side effect: it causes systemic vasodilation, leading to a sudden drop in blood pressure (hypotension) in up to 80% of patients. This isn't just uncomfortable for the mother (causing nausea and vomiting); it can also reduce blood flow to the placenta, potentially distressing the fetus.

While phenylephrine is currently the first-line drug used to maintain blood pressure, it can sometimes cause a decrease in maternal heart rate. Methoxamine is a "purer" $\alpha_1$ agonist that theoretically offers better heart protection by reducing myocardial oxygen consumption. However, until now, there was no clear consensus on the optimal dose for a continuous prophylactic infusion of methoxamine in this specific patient population.

Methods

The researchers conducted a randomized, double-blind, dose-response study involving 80 healthy pregnant women (parturients) scheduled for elective C-sections.

  • Grouping: Patients were randomly assigned to one of four groups receiving methoxamine at fixed rates: 1, 2, 3, or 4 $\mu$g/kg/min.
  • Procedure: Infusions began immediately after the spinal injection.
  • Definition of Success: An "adequate response" was defined as the absence of hypotension (maintaining systolic blood pressure $\ge$ 80% of baseline and $\ge$ 90 mmHg) until the baby was delivered.
  • Analysis: The team used a probit regression model—a standard statistical tool for dose-response studies—to calculate the ED50 and ED95 values.

Datasets

As a clinical trial, the "dataset" consisted of the clinical and physiological data from the 80 recruited parturients at the Women’s Hospital, Zhejiang University. The study followed strict inclusion criteria (singleton pregnancy, ASA status $\le$ 2) and exclusion criteria (pre-existing hypertension, BMI > 30, or fetal abnormalities) to ensure a controlled experimental environment.

Key Insights and Ideas

  • Dose-Dependent Efficacy: There was a clear, statistically significant trend: as the dose of methoxamine increased, the incidence of hypotension plummeted (from 75% in the 1 $\mu$g group to just 10% in the 4 $\mu$g group).
  • The "Duration" Factor: The study highlighted that the duration of hypotension might be more critical for the baby than the severity. In the lowest-dose group (M1), where hypotension lasted the longest, babies had lower Apgar scores and poorer blood gas results.
  • Heart Rate Stability: Interestingly, despite methoxamine's potential to cause bradycardia (slow heart rate), there were no significant differences in the incidence of bradycardia across the four dose groups, suggesting the drug is well-tolerated within this range.
  • Weight-Based Precision: The authors argue that weight-based infusion is more accurate than fixed-dose boluses, helping to avoid under-dosing in heavier patients or over-dosing in lighter ones.

Key Results

The primary quantitative findings were the calculated effective doses:

  • ED50: 2.178 $\mu$g/kg/min (95% CI: 1.564 to 2.680).
  • ED95: 4.821 $\mu$g/kg/min (95% CI: 3.951 to 7.017).

Secondary outcomes showed that the 1 $\mu$g/kg/min group (M1) had significantly worse neonatal outcomes, including lower 1-minute Apgar scores and lower umbilical arterial $PaO_2$, likely due to the inadequate prevention of maternal hypotension.

Limitations and Future Work

The authors acknowledge several limitations:

  1. Small Sample Size: While 80 patients is sufficient for probit regression, it is a small cohort for detecting rare adverse events.
  2. Short Observation Window: Hemodynamic data was only collected for the first 12 minutes after spinal anesthesia.
  3. Healthy Population: The study excluded high-risk patients (e.g., those with pre-eclampsia or obesity), so the results may not generalize to all obstetric cases.
  4. Lack of Direct Comparison: While the paper discusses phenylephrine, this study did not include a phenylephrine control group for a head-to-head comparison.

Future Work: The researchers suggest that further studies should focus on high-risk parturients and conduct direct comparisons between methoxamine and phenylephrine to definitively establish methoxamine's place in routine clinical practice.

Summary updated

Abstract

<title>Abstract</title> Background: α-receptor agonists have been reported to be safe and effective for treating or preventing spinal-induced hypotension during cesarean delivery. As a pure α1 adrenergic agonist, methoxamine has potential advantages of reducing myocardial oxygen consumption and protecting the heart in obstetric patients compared to phenylephrine. The aim of this study was to determine the optimal prophylactic methoxamine infusion dose that would be effective for preventing spinal-induced hypotension in 50% (ED50) and 95% (ED95) of parturients. Methods: Eighty parturients with a singleton pregnancy scheduled for elective cesarean delivery were randomly allocated to receive prophylactic methoxamine infusion at one of four different fixed-rates: 1μg/kg/min (group M1), 2μg/kg/min (group M2), 3μg/kg/min (group M3), or 4μg/kg/min (group M4). An adequate response was defined as absence of hypotension (maternal SBP &lt;80% of baseline or SBP &lt; 90 mmHg). The values for ED50 and ED95 of prophylactic methoxamine infusion were determined by probit regression model. The outcomes of maternal hemodynamics and fetal status were compared among the groups. Results: The calculated ED50 and ED95 (95% confidence interval) of prophylactic methoxamine infusion dose were 2.178 (95% CI 1.564 to 2.680) μg/kg/min and 4.821 (95% CI 3.951 to 7.017) μg/kg/min, respectively. The incidence of hypotension decreased with increasing methoxamine infusion dose (15/20, 11/20, 7/20 and 2/20 in group M1, M2, M3 and M4 respectively, P &lt; 0.001). 1-minute Apgar scores and umbilical arterial PaO2 were lower but umbilical arterial PaCO2 was higher in Group M1. No difference was found in the other incidence of adverse effects and neonatal outcomes among groups. Conclusions: Under the conditions of this study, when prophylactic methoxamine infusion was given at a fixed-rate based on body weight for preventing spinal-induced hypotension in obstetric patients, the values for ED50 and ED95 were 2.178μg/kg/min and 4.821μg/kg/min respectively.
BibTeX
@inproceedings{fu2020randomised,
  author = {Feng Fu and Yu-Wen Tang and Hong Chen and Cuicui Jiao and Na Ma and Xinzhong Chen},
  title = {{A Randomised Dose-Response Study of Prophylactic Methoxamine Infusion for Preventing Spinal-induced Hypotension during Cesarean Delivery}},
  booktitle = {Research Square},
  year = {2020},
  doi = {10.21203/rs.2.19385/v3},
}
Figure